Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Voyageur Pharmaceuticals ( (TSE:VM) ) has issued an update.
Voyageur Pharmaceuticals has secured 100% ownership of the proprietary “Mueller Process” iodine extraction technology and appointed its inventor, Dr. Brian Mueller, as Director of Chemistry, strengthening its in-house scientific capabilities and tightening control over key intellectual property. The deal is expected to enhance the company’s iodine extraction projects in the Anadarko Basin by improving cost efficiency, operational flexibility and long-term supply security, while potentially enabling Voyageur’s Streamlined API process to bypass traditional iodine flake production and manufacture iodine drugs directly from brine, positioning the firm to pursue one of the lowest cost structures in the multibillion‑dollar iodine contrast drug market and to tap additional mineral opportunities at its Paradox Basin claims.
The most recent analyst rating on (TSE:VM) stock is a Sell with a C$0.16 price target. To see the full list of analyst forecasts on Voyageur Pharmaceuticals stock, see the TSE:VM Stock Forecast page.
Spark’s Take on TSE:VM Stock
According to Spark, TipRanks’ AI Analyst, TSE:VM is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and rising cash burn that implies funding/dilution risk), only partly offset by low leverage and positive equity. Technical indicators are broadly neutral and provide limited support, while valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on TSE:VM stock, click here.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian developer of pharmaceutical-grade barium and iodine used in medical imaging contrast media. The company focuses on vertically integrating its supply chain, from mineral extraction through to finished contrast agents, with a particular emphasis on cost-efficient, domestically produced iodine-based contrast drugs for the North American market.
YTD Price Performance: 2.94%
Average Trading Volume: 93,641
Technical Sentiment Signal: Buy
Current Market Cap: C$31.23M
Learn more about VM stock on TipRanks’ Stock Analysis page.